Anti-topoisomerase antibodies

Epitopes and subtypes

Anti Scl-70 antibodies (also called anti-topoisomerase I after the type I topoisomerase target) is a type of antinuclear autoantibody seen mainly in diffuse systemic scleroderma, but is also seen the more limited form of systemic scleroderma called CREST syndrome. However, CREST syndrome is more closely associated with anti-centromere antibodies. Scl-70 antibodies are associated with more severe scleroderma disease.

Anti-topoisomerase antibodies can be classified according to their immunoglobulin class (IgM, IgG or IgA). IgG-ATA is found most frequently in scleroderma, with IgA being quite common but IgM very infrequent.

Pathology

Topoisomerase I is an enzyme that relaxes the strain on DNA by nicking and ligating the DNA. ATA inhibits the activity of this enzyme. Since this activity occurs in the nucleus of the cell ATA is a form of antinuclear antibody. Scleroderma results from the overproduction of collagen in affected tissues, one study claims that there is an increased density of Topoisomerase I sites in the collagen genes, and that the antibodies may be altering transcription at these loci. ATA correlates with rapid progression of disease.

In systemic lupus erythematosus ATA are associated with nephritis.

Increases in ATA+ in scleroderma and SLE are associated with increases in serum CTLA4.

Genetics

HLA-DR2 (DR15 and DR16) are associated with scleroderma and systemic sclerosis. It has been found that patients with ATA that recognize the ET4 domain of topoisomerase were frequently HLA-DR2, and in another population study it was found that DR-15 is associated with ATA in systemic sclerosis. In addition to HLA-DR, the protein tyrosine phosphatase, non-receptor type 22 (lymphoid) (1p13.2 - ), "CT/TT" genotype showed significant association with anti-topo I. The gene (6p21.3, HLA complex) has also been found in association with ATA+ sclerosis.

References

References

1. (1986). "Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I". Chromosoma.
2. (2007). "Robbins Basic Pathology". Saunders.
3. JB Imboden, DB Hellmann, JH Stone. Current Rheumatology Diagnosis & Treatment, Second Edition. McGraw-Hill, 2007.
4. (1989). "Marker antibodies in scleroderma and polymyositis: clinical associations". Clinical Rheumatology.
5. Hildebrandt S. (1990). "The IgG, IgM, and IgA isotypes of anti-topoisomerase I and anticentromere autoantibodies". Arthritis & Rheumatism.
6. (1986). "Inhibition of topoisomerase I by antibodies in sera from scleroderma patients". FEBS Letters.
7. Douvas A. (1988). "Does Sc1-70 modulate collagen production in systemic sclerosis?". The Lancet.
8. Perera A. (2007). "Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody". Arthritis & Rheumatism.
9. (2006). "Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis". Clinical Rheumatology.
10. Sato S. (2004). "Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis". Rheumatology.
11. (2002). "Association of CTLA-4 with systemic sclerosis in Japanese patients". Clinical and Experimental Rheumatology.
12. (1993). "Autoantigenic epitopes on DNA topoisomerase I. Clinical and immunogenetic associations in systemic sclerosis". Arthritis and Rheumatism.
13. Joung CI. (2006). "Association between the HLA-DRB1 gene and clinical features of systemic sclerosis in Korea". Scandinavian Journal of Rheumatology.
14. Gourh P. (2006). "Association of the protein tyrosine phosphatase, non-receptor type 8 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis". Arthritis and Rheumatism.
15. (2005). "Association of TAP1 and TAP2 gene polymorphisms with systemic sclerosis in Korean patients". Human Immunology.